Phase 3 Studies Herald More Options for Metastatic Breast Cancer
Dr Alan Lyss details the results and clinical implications of the EMERALD, PHOEBE, and DESTINY-Breast03 trials.
All articles by Alan P. Lyss, MD
Do Antibiotics Affect Outcomes of Immunotherapy in Lung Cancer?
A meta-analysis revealed inferior responses, progression-free survival, and overall survival in patients exposed to antibiotics.
Genetic Differences May Partly Explain Racial/Ethnic Disparities in Early-Onset Colorectal Cancer
Data from the GENIE registry revealed distinct genomic patterns in patients of different races/ethnicities.
Equal Access to Care May Eliminate Racial Disparities in Lung Cancer Outcomes
One study suggested that modifiable factors could improve racial disparities in the stage at which lung cancer is diagnosed.
Adult Participation in Cancer Trials Higher Than Previously Thought
Enrollment rates varied widely by study type and institution.
First-Line Immunotherapy Continues to Best Chemo in Malignant Pleural Mesothelioma
Data suggest nivolumab plus ipilimumab provides a long-term survival benefit in patients with unresectable malignant pleural mesothelioma.
Changes in Clinical Trial Conduct Prompted by the COVID-19 Pandemic Should Persist
The AACR COVID-19 and Cancer Task Force recommends keeping changes to clinical trial practices that were prompted by the pandemic.
KRAS G12C Mutations in Metastatic Colorectal Cancer: Questions Remain
Dr Alan Lyss reviews studies of KRAS G12C mutations in metastatic colorectal cancer.
On-Treatment Ki-67: A Promising Prognostic Marker for Early Breast Cancer Management
Dr Alan Lyss reviews results from the high-risk cohort of the WSG-ADAPT HR+/HER2- trial.
- Loading...
Loading...
Next post in Breast Cancer
Loading... 
Loading...